

Special Issue

10th Anniversary of *Biomedicines*—Mitochondrial Biology

Message from the Guest Editor

The year 2023 marks the 10th anniversary of *Biomedicines*, a peer-reviewed, open-access journal in the biomedical field. To celebrate this significant milestone, we aim to publish a Special Issue entitled “10th Anniversary of *Biomedicines*—Mitochondrial Biology”. This mitochondrion is well known as the powerhouse of the eukaryotic cell, but it also plays a pivotal role in the regulation of signaling pathways, and in cell differentiation, proliferation and death. Thus, mitochondrial dysfunction is linked to numerous human pathologies, ranging from rare diseases to diseases with a very high societal impact (e.g., cancer, neurodegenerative diseases). A better understanding of the mitochondrial function in normal and pathological states is crucial for an improved management of these diseases and for the development of innovative therapies. This Special Issue focuses on mitochondrial biology, aiming to collect submissions of original research articles or review articles describing the current state of the art of the field.

Guest Editor

Dr. Marie-Pierre Golinelli-Cohen

Institut de Chimie des Substances Naturelles, CNRS Centre National de la Recherche Scientifique, Gif-sur-Yvette, France

Deadline for manuscript submissions

closed (15 December 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/106500

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).